Zura Bio Limited Class A (ZURA)

Over the past six months, Zura Bio's stock has been influenced by several events. In February 2026, the company participated in the Guggenheim Emerging Outlook: Biotech Summit, and its shares experienced a decline following conference participation announcements, though they partially recovered. In January 2026, Sandeep Kulkarni was appointed as CEO, and the company anticipated topline data for its TibuSHIELD trial in Q4 2026 and for the TibuSURE study in the first half of 2027. In November 2025, Zura Bio reported its Q3 financial results, with $139.0 million in cash and cash equivalents, expected to fund operations through 2027. In August 2025, the company reported its Q2 financial results and the initiation of the TibuSHIELD global Phase 2 clinical study. In July 2025, inducement grants were reported to newly hired employees. Between February 3, 2025, and February 2, 2026, the share price increased by 235.47%.

Information regarding demand seasonality for Zura Bio Ltd.'s products and services is not readily available. As a clinical-stage biotechnology company, its focus is on drug development and clinical trials rather than commercial product sales, which would typically exhibit demand seasonality.

Zura Bio Ltd. is a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases. Their approach targets multiple mechanisms of immune system imbalance to improve efficacy and safety. Their pipeline includes Tibulizumab (ZB-106), currently in Phase 2 clinical studies for systemic sclerosis and hidradenitis suppurativa; Torudokimab (ZB-880), a monoclonal antibody that has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that has completed Phase 1/1b clinical studies. The company was founded in 2022 and is headquartered in Henderson, Nevada.

Zura Bio Limited develops medicines for immune and inflammatory disorders in the United States and is headquartered in Henderson, Nevada. The company was incorporated in the United Kingdom on January 17, 2022.

In the past year, media coverage of brands linked with Zura Bio Limited included six events, primarily company updates and people movement. The information highlights corporate and clinical development news, such as financial results, pipeline progress, and executive appointments. There is no indication of events negatively affecting Zura Bio Ltd.'s brand reputation.

Zura Bio Limited has 87 institutional owners and shareholders, holding a total of 41,675,805 shares. Approximately 48.78% of the company's stock is owned by institutional investors, 7.69% by insiders, and 43.54% by public companies and individual investors. Major institutional owners include Suvretta Capital Management, VR Adviser, JPMorgan Chase & Co, Great Point Partners Llc, Adage Capital Partners Gp, L.l.c., Pfizer Inc, Braidwell Lp, Ikarian Capital, LLC, Armistice Capital, Llc and Affinity Asset Advisors, LLC. Notable individual insider owners include Someit Sidhu and Amit Munshi.